ENDRA Life Sciences Strengthens Clinical Foundation for TAEUS Liver
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
"During the first quarter, we continued to strengthen the clinical foundation for TAEUS Liver while maintaining disciplined operational execution," said Alexander Tokman, CEO of ENDRA Life Sciences. "The recently announced multi-site validation data demonstrated strong agreement with MRI-PDFF across operators and patient populations. These data reinforce our belief that TAEUS Liver has the potential to deliver a practical, point-of-care solution for the large and growing population affected by steatotic liver disease. We remain focused on advancing our regulatory and commercialization strategy while managing our resources carefully."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NDRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NDRA
Wall Street analysts forecast NDRA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.520
Low
30.00
Averages
30.00
High
30.00
Current: 5.520
Low
30.00
Averages
30.00
High
30.00
No data
About NDRA
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Endra Life Sciences Reports Q1 Financial Results
- Financial Performance: Endra Life Sciences reported a Q1 GAAP EPS of -$1.09, indicating challenges in profitability that could undermine investor confidence and exert downward pressure on the stock price.
- Cash Position: As of March 31, 2026, Endra had approximately $356,000 in cash and cash equivalents, a liquidity level that may restrict its operational and investment capabilities, particularly in R&D.
- Digital Asset Treasury: The company holds about $2.4 million in its Digital Asset Treasury, which not only forms part of its capital management strategy but may also provide support for future funding needs, despite the current cash flow challenges.
- Market Reaction Outlook: Given the poor financial performance in Q1, the market may adopt a cautious stance towards Endra's future developments, prompting investors to closely monitor subsequent financial improvement measures and strategic adjustments.
See More
Endra Life Sciences Reports Disappointing FY Earnings
- Disappointing Earnings Report: Endra Life Sciences reported a FY GAAP EPS of -$8.93, missing expectations by $2.34, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, Endra had approximately $762,000 in cash and cash equivalents, reflecting tight liquidity management that may limit future operational and investment capabilities.
- Digital Asset Holdings: The company also holds approximately $2.0 million in digital assets, which serves as a crucial component of its capital management strategy, potentially providing additional financial flexibility but also exposing the company to market volatility risks.
- Market Sentiment: Following the disappointing earnings, market sentiment towards Endra is expected to be cautious, prompting investors to reassess their strategies, which may lead to downward pressure on the stock price in the short term.
See More
ENDRA LIFE SCIENCES INC - BOARD TO ASSESS STRATEGIC INVESTMENTS, MERGERS, ASSET DISPOSALS, OR COMPANY SALE
- Strategic Evaluations: The board is tasked with evaluating strategic investments, mergers, and asset sales.
- Company Sales: The focus includes the potential sale of companies as part of their strategic assessments.
See More
AMTD Digital Inc Reports 565.7% Revenue Growth in FY25
- Significant Revenue Growth: AMTD Digital Inc reported a staggering 565.7% year-over-year increase in FY25 revenue, reaching $136.1 million, which significantly enhances the company's financial performance and indicates strong market demand for its services.
- Stock Price Surge: Following the positive earnings report, AMTD Digital's shares jumped 24.4% to $2.18 in pre-market trading, reflecting investor optimism regarding the company's future growth potential and profitability.
- Positive Market Reaction: The robust financial results have garnered widespread attention in the market, potentially attracting more investors and further driving up the stock price while bolstering overall market confidence in the company.
- Strategic Implications: The revenue growth not only strengthens AMTD Digital's market position but also provides financial resources for future expansion and investments, enhancing its competitiveness in the digital finance sector.
See More
Danaher Exceeds Q4 Earnings Guidance but Faces Market Skepticism
- Revenue Growth: Danaher's Q4 2025 revenue rose 4.6% year-over-year to $6.84 billion, surpassing the analyst consensus estimate of $6.81 billion, indicating strong performance in the medical equipment sector.
- Adjusted EPS: Adjusted earnings per share increased by 4.2% to $2.23, exceeding the market expectation of $2.15, reflecting the company's ongoing improvement in profitability.
- Cautious Market Outlook: Despite better-than-expected core revenue growth guidance, management's outlook for 2026 remains conservative, anticipating core revenue growth between 3% and 6%, highlighting uncertainty in market demand.
- Bioprocessing Recovery: The bioprocessing segment saw core revenue growth of 8%, driven by strong demand for consumables, indicating a strengthening recovery in this key market.
See More
ENDRA Launches Low-Cost TAEUS Liver Detection Technology Under $200
- Technology Validation: ENDRA's TAEUS device demonstrates a 100% PPV and 94% NPV at liver fat fraction thresholds of 12-22%, with an accuracy of 95%, showcasing its potential in clinical decision-making by effectively distinguishing between mild and severe steatosis patients.
- Cost Advantage: With an anticipated cost of under $200, TAEUS offers a significant reduction compared to the $2,500 MRI-PDFF exams, enabling frequent monitoring every eight weeks, thus lowering the high screening costs associated with drug development.
- Market Opportunity: As over 50 MASLD/MASH and 250 GLP-1 trials are ongoing globally, TAEUS's high accuracy and low cost position it as an ideal choice for drug developers and payors, significantly reducing overall clinical trial costs.
- Strategic Pathway: ENDRA plans to engage with the FDA in 2026 to align on clinical decision thresholds in multicenter studies, further advancing TAEUS's market application and regulatory approval.
See More
Endra Life Sciences Reports Q1 Financial Results
- Financial Performance: Endra Life Sciences reported a Q1 GAAP EPS of -$1.09, indicating challenges in profitability that could undermine investor confidence and exert downward pressure on the stock price.
- Cash Position: As of March 31, 2026, Endra had approximately $356,000 in cash and cash equivalents, a liquidity level that may restrict its operational and investment capabilities, particularly in R&D.
- Digital Asset Treasury: The company holds about $2.4 million in its Digital Asset Treasury, which not only forms part of its capital management strategy but may also provide support for future funding needs, despite the current cash flow challenges.
- Market Reaction Outlook: Given the poor financial performance in Q1, the market may adopt a cautious stance towards Endra's future developments, prompting investors to closely monitor subsequent financial improvement measures and strategic adjustments.
See More
Endra Life Sciences Reports Disappointing FY Earnings
- Disappointing Earnings Report: Endra Life Sciences reported a FY GAAP EPS of -$8.93, missing expectations by $2.34, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, Endra had approximately $762,000 in cash and cash equivalents, reflecting tight liquidity management that may limit future operational and investment capabilities.
- Digital Asset Holdings: The company also holds approximately $2.0 million in digital assets, which serves as a crucial component of its capital management strategy, potentially providing additional financial flexibility but also exposing the company to market volatility risks.
- Market Sentiment: Following the disappointing earnings, market sentiment towards Endra is expected to be cautious, prompting investors to reassess their strategies, which may lead to downward pressure on the stock price in the short term.
See More
ENDRA LIFE SCIENCES INC - BOARD TO ASSESS STRATEGIC INVESTMENTS, MERGERS, ASSET DISPOSALS, OR COMPANY SALE
- Strategic Evaluations: The board is tasked with evaluating strategic investments, mergers, and asset sales.
- Company Sales: The focus includes the potential sale of companies as part of their strategic assessments.
See More
AMTD Digital Inc Reports 565.7% Revenue Growth in FY25
- Significant Revenue Growth: AMTD Digital Inc reported a staggering 565.7% year-over-year increase in FY25 revenue, reaching $136.1 million, which significantly enhances the company's financial performance and indicates strong market demand for its services.
- Stock Price Surge: Following the positive earnings report, AMTD Digital's shares jumped 24.4% to $2.18 in pre-market trading, reflecting investor optimism regarding the company's future growth potential and profitability.
- Positive Market Reaction: The robust financial results have garnered widespread attention in the market, potentially attracting more investors and further driving up the stock price while bolstering overall market confidence in the company.
- Strategic Implications: The revenue growth not only strengthens AMTD Digital's market position but also provides financial resources for future expansion and investments, enhancing its competitiveness in the digital finance sector.
See More
Danaher Exceeds Q4 Earnings Guidance but Faces Market Skepticism
- Revenue Growth: Danaher's Q4 2025 revenue rose 4.6% year-over-year to $6.84 billion, surpassing the analyst consensus estimate of $6.81 billion, indicating strong performance in the medical equipment sector.
- Adjusted EPS: Adjusted earnings per share increased by 4.2% to $2.23, exceeding the market expectation of $2.15, reflecting the company's ongoing improvement in profitability.
- Cautious Market Outlook: Despite better-than-expected core revenue growth guidance, management's outlook for 2026 remains conservative, anticipating core revenue growth between 3% and 6%, highlighting uncertainty in market demand.
- Bioprocessing Recovery: The bioprocessing segment saw core revenue growth of 8%, driven by strong demand for consumables, indicating a strengthening recovery in this key market.
See More
ENDRA Launches Low-Cost TAEUS Liver Detection Technology Under $200
- Technology Validation: ENDRA's TAEUS device demonstrates a 100% PPV and 94% NPV at liver fat fraction thresholds of 12-22%, with an accuracy of 95%, showcasing its potential in clinical decision-making by effectively distinguishing between mild and severe steatosis patients.
- Cost Advantage: With an anticipated cost of under $200, TAEUS offers a significant reduction compared to the $2,500 MRI-PDFF exams, enabling frequent monitoring every eight weeks, thus lowering the high screening costs associated with drug development.
- Market Opportunity: As over 50 MASLD/MASH and 250 GLP-1 trials are ongoing globally, TAEUS's high accuracy and low cost position it as an ideal choice for drug developers and payors, significantly reducing overall clinical trial costs.
- Strategic Pathway: ENDRA plans to engage with the FDA in 2026 to align on clinical decision thresholds in multicenter studies, further advancing TAEUS's market application and regulatory approval.
See More
